ErVaccine Technologies, in collaboration with Centre Leon Berard hospital / Cancer Research Center of Lyon, is thrilled to announce the selection of their research collaborative project (PRCE) grant proposal by French National Research Agency (ANR), for a total amount close to 500k€ of non-dilutive funding in the form of grants. The purpose of the research program is to provide the pre-clinical proof-of-concept of TCR engineered T-cells targeting endogenous retrovirus (HERV) antigens as a new strategy in the treatment of Triple Negative Breast Cancer. This approach would have the advantage of being transferable to other tumors overexpressing HERV antigens.